Dr. Mascarenhas describes his memorable updates from the 2022 ASH Annual Meeting, including what to expect in the near future for patients with myelofibrosis.

This activity is supported by educational grants from Bristol Myers Squibb Company, CTI BioPharma, and Sierra Oncology.

In this activity, Dr. Sandra Kurtin describes the importance of differentiating between intolerance of the drug versus symptoms of the disease.

This activity is supported by educational grants from Bristol Myers Squibb Company, CTI BioPharma, and Sierra Oncology.

It is very important to establish the goals of therapy with patients. In this activity, Dr. Kuykendall and Dr. Bose explain how to determine treatment success based on individual goals.

This activity is supported by educational grants from Bristol Myers Squibb Company, CTI BioPharma, and Sierra Oncology.

In this activity, Dr. Kuykendall and Dr. Bose discuss which patients are predicted to respond to a JAK inhibitor.

This activity is supported by educational grants from Bristol Myers Squibb Company, CTI BioPharma, and Sierra Oncology.

As more therapies become available for patients with myelofibrosis, it can be difficult to choose the best option for second-line treatment. Dr. Bose discusses what patient factors to consider.

This activity is supported by educational grants from Bristol Myers Squibb Company, CTI BioPharma, and Sierra Oncology.

There are various definitions in clinical trials relating to ruxolitinib failure. Dr. Mascarenhas explains how you can decide on switching to an alternative therapy or a combination strategy.

This activity is supported by educational grants from Bristol Myers Squibb Company, CTI BioPharma, and Sierra Oncology.